The UCLA Inflammatory Bowel Disease Research Center, established in 2007, focuses on multiple aspects of the pathophysiology, therapy, and diagnosis of IBD with some of the funding from the National Institutes of Health (NIH), the Broad Foundation, and the Crohn's & Colitis Foundation of America, Inc. Their discoveries are not only helping to unravel the mysteries driving IBD pathogenesis at the molecular and cellular levels, but they are also providing targets for new therapeutic approaches — some of which are currently under investigation.
Clinical Research Alliance
UCLA is a member of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America. The mission of the Clinical Research Alliance is to ask and answer clinically relevant questions that would not otherwise be studied, with the ultimate goal of improving the life of patients with IBD.Learn more >
Corrona Inflammatory Bowel Disease Registry
The objective of the Corrona Inflammatory Bowel Diseases (IBD) Registry is to create a national cohort of patients with Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis (IC). Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of IBD.Corrona IBD Registry
| Enroll in the Registry
Our center conducts cutting-edge biomedical and health-related research studies that include both interventional and observational studies.
1. View current list of clinical trials >
The group headed by Dr. Charalabos “Harry” Pothoulakis is internationally recognized for its work in describing how microRNAs are involved, and in developing treatment strategies that capitalize on these findings.
Pothoulakis Laboratory >
Our work in the microbiome realm includes a group headed by Dr. Jonathan P. Jacobs that is investigating how the intestinal microbiome contributes to IBD development.
Jacobs Laboratory >
Center for Systems Biomedicine
The center is focused on how the environment influences IBD pathogenesis through changes in the epigenome and microbiome. In the epigenome category, Dr. Harry Pothoulakis and his colleagues are leaders in the use of cutting-edge approaches such as systems science and artificial intelligence to discover the role of DNA methylation and histone modifications in the development of IBD.
Center for Systems Biomedine >
G. Oppenheimer Center for Neurobiology of Stress and Resilience
Dr. Emeran A. Mayer and his colleagues are conducting pioneering studies exploring the interactions between IBD and the nervous system, amid mounting interest in the role of brain alterations in IBD pathogenesis.
G. Oppenheimer Center for Neurobiology of Stress and Resilience >